Reasons to invest in Bactiguard
A scalable license-focused business model with operational leverage
Bactiguard operates through license partnerships with leading global MedTech companies that apply our infection prevention technology to their medical devices and sell them under their own brand name or co-branded with Bactiguard. Our license revenues have three components: we receive revenues for coating and process development, we receive revenues for the right to use the coating technology on medical devices within a specific application and geographical area, and we receive royalties; a variable remuneration once the license partners’ products reach the market. The revenues are generated across three partnership phases: application development, exclusivity and license. The license-focused business model is scalable with strong operational leverage.
Access to the global MedTech-market through license partnerships
Through license partnerships with leading global MedTech companies, Bactiguard is well-positioned to capitalize on the expanding global medical device market where our five strategic therapeutic areas Orthopedics, Cardiology, Neurology, Urology, and Vascular Access, are projected to combined represent a potential market exceeding USD 70 billion by 2030, based on internal analysis. Our innovative infection prevention technology meets a pressing unmet medical need. As a reference, between 40 to 60 percent of all healthcare-associated infections stem from medical devices, elevating patient risks and healthcare costs. Compatible with most medical device materials, Bactiguard’s technology enhances patient safety and provides our partners with a competitive edge in a dynamic, high-growth market.
Antibiotics resistance is one of the most urgent health risks of our time and threatens to undo a century of medical progress.
Tedros Adhanom Ghebreyesus
Director General of WHO
A safe, biocompatible, and effective technology with strong patent protection
Bactiguard’s offering is based on clinical evidence which is a significant strategic advantage. It is clinically proven that our technology is safe, biocompatible, and significantly reduces the risk of medical device related infections. More than 40 clinical studies involving more than 100,000 patients have been performed over the years. More than 245 million Bactiguard coated Foley catheters have been sold so far with no adverse event reported associated with the coating. We are a knowledge and specialist organization, where intellectual property (IP), including patents, are an integral part of the strategy. Bactiguard has strong patent protection across different patents within nine relevant patent families. We continuously monitor and invest in our IP portfolio, which above all covers the coating but also the coating processes.
Contributing to a healthier world by preventing infections
Finding ways to prevent infections, and consequently decrease the use of antibiotics, is a priority on the global healthcare and sustainability agenda. Our technology forms an important link in the healthcare value chain in the fight against antimicrobial resistance, healthcare-associated infections and sepsis, as it significantly reduces the risk of medical device related infections. Clinical studies have shown that the risk of catheter-associated urinary tract infections is reduced by 69 percent, of ventilator- associated pneumonia by 53 percent and of catheter- related blood infections by 52 percent when using medical devices with Bactiguard’s coating technology.